

Evolving the treatment practice of advanced EGFRm NSCLC

Monday 30 September 2019, 13:00–14:30


Bilbao Auditorium, Hall 5, Fira Gran Via, Barcelona, Spain

Faculty



Johan Vansteenkiste

University Hospital KU Leuven
Leuven
Belgium



Frank Griesinger

Pius-Hospital Oldenburg
Oldenburg
Germany



Pasi A. Jänne

Dana-Farber Cancer Institute
Boston, Massachusetts
USA



Rachel E. Sanborn

Providence Cancer
Institute Franz Clinic
Portland, Oregon
USA

Agenda

Chair **Johan Vansteenkiste**

Newly diagnosed advanced EGFRm NSCLC – what information will help improve our treatment decision?

Pasi A. Jänne

Planning the patient journey – how can we maximise all of the treatment opportunities?

Frank Griesinger

Exploring treatment options beyond progression

Rachel E. Sanborn

Panel discussion and audience Q&A

Faculty and audience

Light refreshments are available prior to the symposium

AstraZeneca's sustainability priorities



Access to healthcare



Environmental protection



Ethics and transparency



Find out more about AstraZeneca's Commitment to Sustainability on our website

